CME Group (CME)
(Delayed Data from NSDQ)
$197.25 USD
-0.19 (-0.10%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $197.25 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
CME Group (CME) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$218.80 | $250.00 | $187.00 | 10.82% |
Price Target
Based on short-term price targets offered by 15 analysts, the average price target for CME Group comes to $218.80. The forecasts range from a low of $187.00 to a high of $250.00. The average price target represents an increase of 10.82% from the last closing price of $197.44.
Analyst Price Targets (15)
Broker Rating
CME Group currently has an average brokerage recommendation (ABR) of 2.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 16 brokerage firms. The current ABR compares to an ABR of 2.50 a month ago based on 16 recommendations.
Of the 16 recommendations deriving the current ABR, seven are Strong Buy, representing 43.75% of all recommendations. A month ago, Strong Buy represented 43.75%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 7 | 7 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 6 | 6 | 6 | 7 | 7 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 3 | 3 | 3 | 2 | 2 |
ABR | 2.50 | 2.50 | 2.50 | 2.38 | 2.38 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/10/2024 | Not Identified | Not Identified | Hold | Hold |
7/3/2024 | Keefe Bruyette & Woods | Kyle K Voigt | Hold | Hold |
7/2/2024 | Goldman Sachs | Alexander Blostein | Strong Sell | Strong Sell |
4/25/2024 | Rosenblatt Securities | Andrew Bond | Strong Sell | Strong Sell |
4/24/2024 | Not Identified | Not Identified | Hold | Hold |
4/24/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/12/2024 | Piper Sandler | Patrick Moley | Strong Buy | Strong Buy |
4/8/2024 | Atlantic Equities | Simon Clinch | Strong Buy | Strong Buy |
3/6/2024 | Argus Research Corp. | Stephen Biggar | Not Available | Strong Buy |
12/15/2023 | UBS | Alex Kramm | Strong Buy | Strong Buy |
10/12/2023 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.50 |
ABR (Last week) | 2.50 |
# of Recs in ABR | 16 |
Average Target Price | $218.80 |
LT Growth Rate | 3.10% |
Industry | Securities and Exchanges |
Industry Rank by ABR | 70 of 252 |
Current Quarter EPS Est: | 2.53 |